Jinfeng Gao, Zhiqing Pang, Qiaozi Wang, Yiwen Tan, Qiyu Li, Haipeng Tan, Jing Chen, Wusiman Yakufu, Zhengmin Wang, Hongbo Yang, Jinyan Zhang, Dili Sun, Xueyi Weng, Qibing Wang, Juying Qian, Yanan Song, Zheyong Huang, Junbo Ge
CD47-SIRPα axis is an immunotherapeutic target in tumor therapy. However, current monoclonal antibody targeting CD47-SIRPα axis is associated with on-target off-tumor and antigen sink effects, which significantly limit its potential clinical application. Herein, a biomimetic nano-degrader is developed to inhibit CD47-SIRPα axis in a site-specific manner through SIRPα degradation, and its efficacy in acute myocardial infarction (AMI) is evaluated. The nano-degrader is constructed by hybridizing liposome with red blood cell (RBC) membrane (RLP), which mimics the CD47 density of senescent RBCs and possesses a natural high-affinity binding capability to SIRPα on macrophages without signaling capacity...
March 13, 2024: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)